Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SepternaSEPN +1.69%12 EV-to-OCF is 13.16 as of Sep. 08, 2026, which is 451% above its 10-year median of 2.39. GuruFocus rates SEPN with a GF Score™ of 12/100. The stock has 2 warning signs investors should review. Among 1,406 Biotechnology companies, Septerna ranks worse than 85.14% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Septerna's Enterprise Value is $1,394.54 Mil.
Septerna's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was $106.01 Mil. Therefore, Septerna's EV-to-OCF for today is 13.16.
The historical rank and industry rank for Septerna's EV-to-OCF or its related term are showing as below:
SEPN'
s EV-to-OCF Range Over the Past 10 Years
Min: -17.77 Med: 2.39 Max: 15.61
Current: 13.16
During the past 4 years, the highest EV-to-OCF of Septerna was 15.61. The lowest was -17.77. And the median was 2.39.
SEPN's EV-to-OCF is ranked worse than 85.14% of 1406
companies
in the Biotechnology industry
Industry Median: -3.7
vs SEPN: 13.16
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Septerna's share price for today is $37.325.
Septerna's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.540.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Septerna EV-to-OCF Related Terms
Septerna EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Septerna's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Septerna's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Septerna EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Septerna's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Septerna's EV-to-OCF falls into.
Septerna's current Enterprise Value is $1,394.54 Mil.
Septerna's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $106.01 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Septerna (SEPN) has a EV-to-OCF of 13.16 as of Sep. 08, 2026. This is 451% above median its historical median of 2.39. According to the industry distribution chart, Septerna ranks #1197 out of 1406 companies in the Biotechnology industry, placing it in the top 85.1%.
Is Septerna's EV-to-OCF too high?
Septerna's current EV-to-OCF of 13.16 is 451% above median its 10-year median of 2.39. Based on the distribution chart, Septerna ranks #1197 out of 1406 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Septerna has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Septerna's EV-to-OCF compare to INBX and NTLA?
According to the Biotechnology industry distribution chart, Septerna ranks #1197 out of 1406 companies for EV-to-OCF. This places Septerna in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Septerna's current EV-to-OCF is 13.16, which is 451% above median its own 10-year median of 2.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Septerna stock overvalued right now?
Septerna (SEPN) has a current EV-to-OCF of 13.16. The current EV-to-OCF is 13.16, which is 451% above median its 10-year median of 2.39. Septerna's overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Septerna (SEPN), the current EV-to-OCF is 13.16 as of Sep. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, GLP-1R, GIPR, and GCGR.
12GF Score
Get the complete analysis for SEPN
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SEPN has been successfully added to your 
